Royal DSM Signs XD Technology Licensing Deal With Amgen (AMGN)
1/15/2013 6:55:12 AM
PARSIPPANY, N.J., Jan. 15, 2013 /PRNewswire/ -- Karen King, President of DSM Biologics, commented "We are pleased to enter into this license agreement with Amgen, a global leader in biopharmaceutical drug development and manufacturing. We believe our proprietary XD®technology will play an important role in the next generation of biopharmaceutical manufacturing." XD® technology is a highly intensified cell culture process with typical titer achievement of 8-to-10 times higher compared to current standard biomanufacturing processes. For some products, titer improvements of up to 15 times have been achieved. It is widely applicable for multiple biological products including proteins, fusion proteins and antibodies, and has been successfully employed across the full spectrum of mammalian cell systems.
Alexander Wessels, President and CEO of DSM Pharmaceutical Products also commented, "DSM continuously strives to provide its clients with added value through our innovative service and technology offerings." With typical XD® titer improvement of 8-10X, a 500L bioreactor can provide a DSM licensee with the same amount of drug substance as a 5000L stainless steel bioreactor at an overall lower cost. DSM's proprietary technologies drive down cost, processing times and capital requirements while increasing flexibility to meet market demand for life saving medications. XD® has also shown impressive results for biosimilars and innovator drugs with respect to both volume and product quality.
Financial terms were not disclosed.
XD® is a registered trademark of DSM
DSM Bright Science. Brighter Living.
Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in Life Sciences and Materials Sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, pharmaceuticals, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM's 22,000 employees deliver annual net sales of about 9 billion. The company is listed on NYSE Euronext. More information can be found at www.dsmbiologics.com and www.dsm.com
For more information:
Director, Marketing and Communications
DSM Pharmaceutical Products
tel. +1 973 257 8160
tel. +1 973 257 8427
This press release may contain forward-looking statements with respect to DSM's future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSM and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is leading.
SOURCE DSM Pharmaceutical Products